Patents by Inventor Johannes Heuckmann

Johannes Heuckmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220036972
    Abstract: The present invention relates to a method for determining the statistical noise level in the calculation of a subject's genetic copy number value in massively parallel nucleic acid sequencing data derived from a sample, as well as a method for determining a subject's genetic copy number value in massively parallel nucleic acid sequencing data derived from a sample and a method to determine a subject's genetic copy number value for stratifying the subject for cancer therapy.
    Type: Application
    Filed: September 16, 2019
    Publication date: February 3, 2022
    Inventors: Tobias ZACHERLE, Johannes HEUCKMANN
  • Publication number: 20210164033
    Abstract: The present invention relates to methods and systems for nucleic acid sequencing. In particular, the present invention relates to methods and systems for reducing the number of false-positives in nucleic acid sequencing. The method comprises: aligning a plurality of genetic reads to a reference genetic sequence; grouping the genetic reads into a plurality of groups; creating a consensus sequence for each group of the plurality of groups by setting a representation of the most abundant nucleotide man_p or a tag N based on a ratio r; and identifying a variation as a true variation if a ratio r* between the number of consensus sequences comprising the tag N at a specific position p and the number of the consensus sequences comprising the variation at the specific position p is below a threshold t*.
    Type: Application
    Filed: May 3, 2018
    Publication date: June 3, 2021
    Inventors: Johannes Heuckmann, Erika Mariotti
  • Publication number: 20200176076
    Abstract: The present invention relates to a method of identifying structural genomic rearrangements in massively parallel nucleic acid sequencing data, as well as an in vitro method to detect genomic alterations for stratifying patients for cancer therapy, including a step of identifying structural genomic rearrangements. Also provided is a method generating a report including information on the identified.
    Type: Application
    Filed: July 9, 2018
    Publication date: June 4, 2020
    Inventors: Johannes HEUCKMANN, Erika MARIOTTI, Tobias ZACHERLE
  • Publication number: 20150329537
    Abstract: The present invention relates to a CDK9 inhibitor, especially a selective CDK9 inhibitor, for use in treating, ameliorating and/or preventing midline carcinoma. Also corresponding methods for treating, preventing or ameliorating midline carcinoma are subject of the present invention. Preferably, NUT midline carcinoma is treated with the CDK9 inhibitors in accordance with the present invention.
    Type: Application
    Filed: August 22, 2012
    Publication date: November 19, 2015
    Applicants: LEADDISCOVERY CENTER GMBH, MAX-PLANCK GESELLSCHAFTZUR FORDERUNG DER WIS SENSCHAFTEN E.V
    Inventors: Axel Choidas, Bert Klebl, Peter Habenberger, Jan Eickhoff, Roman Thomas, Johannes Heuckmann
  • Publication number: 20140303167
    Abstract: The present invention relates to a CDK9 inhibitor, especially a selective CDK9 inhibitor, for use in treating, ameliorating and/or preventing midline carcinoma. Also corresponding methods for treating, preventing or ameliorating midline carcinoma are subject of the present invention. Preferably, NUT midline carcinoma is treated with the CDK9 inhibitors in accordance with the present invention.
    Type: Application
    Filed: August 22, 2012
    Publication date: October 9, 2014
    Applicant: LEAD DISCOVERY CENTER GMBH
    Inventors: Axel Choidas, Bert Klebl, Peter Habenberger, Jan Eickhoff, Roman Thomas, Johannes Heuckmann
  • Publication number: 20140287454
    Abstract: The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to a selective CDK9 inhibitor. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with a selective CDK9 inhibitor is described herein. In particular, the present invention provides for an in vitro method for the identification of a responder for or a patient sensitive to a selective CDK9 inhibitor, whereby the patient is suspected to suffer from NUT midline carcinoma (NMC). The present invention also relates to a method of monitoring or predicting the efficacy of a treatment of NUT midline carcinoma (NMC), wherein treatment with a selective CDK9 inhibitor is in particular envisaged. Also the use of a (transgenic) non-human animal or a (transgenic) cell having at least one rearrangement in the NUT gene for screening and/or validation of a medicament for the treatment NUT midline carcinoma (NMC) is described.
    Type: Application
    Filed: August 22, 2012
    Publication date: September 25, 2014
    Applicants: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., LEAD DISCOVERY CENTER GmbH
    Inventors: Axel Choidas, Bert Klebl, Peter Habenberger, Jan Eickhoff, Roman Thomas, Johannes Heuckmann